Loading people...
Diego Miralles is a Partner at Flagship Pioneering, a venture capital firm based in Cambridge, Massachusetts. Previously, he served as Global Head of Johnson & Johnson Innovation, where he created the JLABS incubator network that has supported hundreds of early-stage startups. He also served as Chief Executive Officer of Vividion Therapeutics, raising over $360 million in venture capital and establishing global industry partnerships before the company's $1.5 billion acquisition by Bayer. Additionally, Miralles was the CEO of Laronde, overseeing a $440 million Series B funding round, and held the role of President at Adaptive Biotechnologies' therapeutics division. He earned his medical degree from the Universidad de Buenos Aires and completed his clinical training at the Mayo Clinic and Cornell University. His career focuses on leading biotechnology investments and advancing early-stage life sciences company creation.
Diego Miralles stands as a prominent Partner at Flagship Pioneering, a unique venture creation firm renowned for originating and developing breakthrough biological innovations. In his pivotal role at Flagship Pioneering, Diego Miralles is instrumental in identifying nascent scientific discoveries and transforming them into viable, impactful companies. Unlike traditional venture capital, Flagship Pioneering builds companies from the ground up, and Miralles' expertise is crucial in guiding these ventures from concept to commercialization.
His investment focus areas are deeply rooted in the life sciences and biotechnology sectors. Diego Miralles is particularly interested in novel therapeutic platforms, drug discovery and development, and disruptive biotechnologies that have the potential to redefine healthcare. He seeks out innovations that can address significant unmet medical needs across various disease areas, including immunology, infectious diseases, oncology, and neuroscience. His strategic insights help shape the scientific direction and business models of Flagship's portfolio companies, ensuring they are poised for long-term success and patient impact.
Diego Miralles brings an impressive career background to Flagship Pioneering, marked by extensive leadership experience in the pharmaceutical industry. Prior to joining Flagship, he held senior executive positions at major global pharmaceutical companies, including Johnson & Johnson, Janssen Pharmaceuticals, and Gilead Sciences. At these organizations, he was responsible for leading global research and development, commercial strategy, and business development initiatives. This rich operational experience provides him with a comprehensive understanding of the entire drug development lifecycle, from early-stage research to regulatory approval and market launch. His deep industry knowledge is invaluable in mentoring founders and navigating the complex landscape of biotech innovation.
While specific notable investments are proprietary to Flagship Pioneering's venture creation model, Diego Miralles' influence is evident across the firm's portfolio of groundbreaking companies. His contributions help foster the creation of enterprises that are pushing the boundaries of science and medicine, aiming to deliver transformative solutions to patients worldwide. Through his work, Diego Miralles continues to solidify Flagship Pioneering's reputation as a leader in life science innovation, driving the next generation of biotech breakthroughs.
Diego Miralles is a Partner at Flagship Pioneering, a leading venture creation firm focused on originating and developing breakthrough biological innovations. He is a seasoned leader in the life sciences and pharmaceutical industries.
Diego Miralles focuses on creating and scaling life science companies at Flagship Pioneering. His investment interests lie in novel therapeutic platforms, drug discovery and development, and disruptive biotechnologies across various disease areas.
Diego Miralles works as a Partner at Flagship Pioneering, a venture creation firm based in Cambridge, Massachusetts, known for building innovative biotech companies.
